Aarti Drugs Limited
NSE: AARTIDRUGS BSE: AARTIDRUGS
Prev Close
477.45
Open Price
475.7
Volume
158,293
Today Low / High
471.15 / 488
52 WK Low / High
312 / 635
Range
451 - 499
Prev Close
477.1
Open Price
471.25
Volume
8,252
Today Low / High
471.25 / 487.8
52 WK Low / High
312.5 / 632.1
Range
450 - 497
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 474.8 (target range: 451 - 499), reflecting a change of -2.65 (-0.55503%). On the BSE, it is listed at 473.6 (target range: 450 - 497), showing a change of -3.5 (-0.7336%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Aarti Drugs Limited Graph
Aarti Drugs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Drugs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 474.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 473.60 | 478.34 | 430.50 - 526.17 |
483.07 | 386.46 - 579.69 | ||
487.81 | 341.47 - 634.15 | ||
Bearish Scenario | 473.60 | 468.86 | 421.98 - 515.75 |
464.13 | 371.30 - 556.95 | ||
459.39 | 321.57 - 597.21 |
Overview of Aarti Drugs Limited
ISIN
INE767A01016
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
496,256
Market Cap
43,334,996,000
Last Dividend
1
Official Website
IPO Date
2003-09-19
DCF Diff
381.91
DCF
93
Financial Ratios Every Investor Needs
Stock Dividend of AARTIDRUGS
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-02-04 | February 04, 25 | 1 | 1 | 2025-02-04 | 2025-02-28 | |
2024-02-06 | February 06, 24 | 1 | 1 | 2024-02-06 | 2024-02-23 | |
2023-02-08 | February 08, 23 | 1 | 1 | 2023-02-08 | 2023-02-26 | |
2022-02-09 | February 09, 22 | 1 | 1 | 2022-02-10 | 2022-03-02 | |
2020-11-03 | November 03, 20 | 2.5 | 2.5 | 2020-11-04 | 2020-11-22 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 2,387.03 Cr | 1,542.10 Cr | 844.93 Cr | 0.3540 | 0.00 Cr | 0.00 Cr | 732.83 Cr | 168.16 Cr | 18.35 | 287.06 Cr | 0.0704 |
2024-03-31 | 2,508.87 Cr | 2,157.71 Cr | 351.17 Cr | 0.1400 | 0.00 Cr | 14.18 Cr | 277.70 Cr | 171.42 Cr | 18.56 | 320.49 Cr | 0.0683 |
2023-03-31 | 2,716.05 Cr | 1,888.51 Cr | 827.54 Cr | 0.3047 | 7.75 Cr | 13.37 Cr | 256.77 Cr | 166.31 Cr | 17.96 | 311.64 Cr | 0.0612 |
2022-03-31 | 2,488.65 Cr | 1,984.82 Cr | 503.83 Cr | 0.2024 | 6.61 Cr | 13.23 Cr | 288.39 Cr | 205.04 Cr | 22.14 | 343.91 Cr | 0.0824 |
2021-03-31 | 2,154.78 Cr | 1,554.47 Cr | 600.31 Cr | 0.2786 | 8.60 Cr | 9.44 Cr | 388.13 Cr | 280.41 Cr | 30.09 | 445.13 Cr | 0.1301 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 7.56 Cr | 2,574.68 Cr | 1,205.34 Cr | 1,369.0000 Cr | 615.07 Cr | 607.51 Cr | 472.93 Cr | 1,189.13 Cr | 0.00 Cr | 0.00 Cr | 22.41 Cr | 836.9700 Cr |
2024-03-31 | 6.74 Cr | 2,432.36 Cr | 1,150.40 Cr | 1,281.5485 Cr | 564.28 Cr | 557.54 Cr | 485.89 Cr | 1,053.94 Cr | 0.00 Cr | 0.00 Cr | 19.97 Cr | 795.5427 Cr |
2023-03-31 | 8.96 Cr | 2,421.40 Cr | 1,228.74 Cr | 1,192.4300 Cr | 608.91 Cr | 599.95 Cr | 516.29 Cr | 885.79 Cr | 4.37 Cr | 0.17 Cr | 18.80 Cr | 932.9800 Cr |
2022-03-31 | 21.61 Cr | 2,207.96 Cr | 1,171.66 Cr | 1,036.3611 Cr | 542.82 Cr | 521.20 Cr | 525.94 Cr | 766.52 Cr | 112.45 Cr | 0.17 Cr | 19.48 Cr | 940.0581 Cr |
2021-03-31 | 8.81 Cr | 1,766.01 Cr | 852.61 Cr | 913.4246 Cr | 350.76 Cr | 341.95 Cr | 415.00 Cr | 684.40 Cr | -39.61 Cr | 0.17 Cr | 17.30 Cr | 595.3559 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 244.5800 Cr | -164.6300 Cr | -82.1200 Cr | 67.4200 Cr | -2.1627 Cr | 4.5800 Cr | -177.1600 Cr | 168.1600 Cr | -7.3700 Cr | -9.0600 Cr | 12.9600 Cr |
2024-03-31 | 358.9232 Cr | -223.6508 Cr | -136.0331 Cr | 132.5887 Cr | -0.7607 Cr | 6.7427 Cr | -226.3345 Cr | 171.4182 Cr | -22.2845 Cr | -9.2673 Cr | 34.2458 Cr |
2023-03-31 | 134.2000 Cr | -163.9700 Cr | 16.5400 Cr | -30.4700 Cr | -13.2300 Cr | 8.3800 Cr | -164.6700 Cr | 224.1800 Cr | 61.3741 Cr | -9.4013 Cr | 5.8200 Cr |
2022-03-31 | 69.6357 Cr | -148.8616 Cr | 92.0251 Cr | -82.3392 Cr | 12.7991 Cr | 21.6120 Cr | -151.9749 Cr | 269.9551 Cr | 195.9490 Cr | -9.5077 Cr | -110.6302 Cr |
2021-03-31 | 154.8497 Cr | -71.6790 Cr | -81.1290 Cr | 66.7189 Cr | 2.0417 Cr | 8.8130 Cr | -88.1308 Cr | 369.0139 Cr | -34.9667 Cr | -23.2052 Cr | -89.1849 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 676.76 Cr | 436.91 Cr | 239.85 Cr | 0.3544 | 208.50 Cr | 62.86 Cr | 6.88 | 94.26 Cr | 0.0929 |
2024-12-31 | 556.60 Cr | 351.39 Cr | 205.21 Cr | 0.3687 | 47.93 Cr | 37.05 Cr | 4.06 | 73.63 Cr | 0.0666 |
2024-09-30 | 598.33 Cr | 434.28 Cr | 164.05 Cr | 0.2742 | 53.32 Cr | 35.01 Cr | 3.83 | 68.53 Cr | 0.0585 |
2024-06-30 | 555.34 Cr | 399.63 Cr | 155.71 Cr | 0.2804 | 51.57 Cr | 33.24 Cr | 3.62 | 66.06 Cr | 0.0599 |
2024-03-31 | 619.99 Cr | 436.55 Cr | 183.44 Cr | 0.2959 | 72.23 Cr | 47.31 Cr | 5.15 | 86.89 Cr | 0.0763 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 7.56 Cr | 15.05 Cr | 22.61 Cr | 751.18 Cr | 472.93 Cr | 1,338.35 Cr | 1,189.13 Cr | 2,574.68 Cr | 1,205.34 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 29.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,277.79 Cr |
2024-09-30 | 11.34 Cr | 18.22 Cr | 29.56 Cr | 682.81 Cr | 470.00 Cr | 1,255.88 Cr | 1,134.06 Cr | 2,429.55 Cr | 1,151.76 Cr |
2024-06-30 | -20.77 Cr | 41.54 Cr | 20.77 Cr | 0.00 Cr | 0.00 Cr | 20.77 Cr | 0.00 Cr | 0.00 Cr | -1,281.97 Cr |
2024-03-31 | 9.43 Cr | 14.03 Cr | 9.43 Cr | 709.51 Cr | 485.89 Cr | 1,320.72 Cr | 1,035.14 Cr | 2,432.36 Cr | 1,150.40 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 62.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-12-31 | 37.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 35.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 33.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 47.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2020-09-30 | September 30, 20 | 4:1 |
2015-03-24 | March 24, 15 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,674.30 | ₹4,017,114,504,000.00 | ₹1,298,302.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,826.50 | ₹1,812,224,128,500.00 | ₹224,031.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,310.60 | ₹1,120,456,017,000.00 | ₹344,198.00 |
Mankind Pharma Limited | MANKIND | ₹2,584.10 | ₹1,066,532,388,716.00 | ₹2,780,534.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,255.00 | ₹1,044,260,073,700.00 | ₹895,466.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹979.95 | ₹986,055,088,500.00 | ₹921,032.00 |
Lupin Limited | LUPIN | ₹1,891.00 | ₹863,649,956,000.00 | ₹1,511,071.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,125.70 | ₹653,808,811,400.00 | ₹1,058,994.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,175.90 | ₹614,041,155,900.00 | ₹15,680,321.00 |
Alkem Laboratories Limited | ALKEM | ₹4,800.00 | ₹573,912,000,000.00 | ₹183,075.00 |
Laurus Labs Limited | LAURUSLABS | ₹789.00 | ₹425,470,617,000.00 | ₹1,476,275.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹1,010.20 | ₹386,469,191,482.00 | ₹322,114.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,450.00 | ₹367,870,800,000.00 | ₹119,065.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,616.10 | ₹326,782,283,200.00 | ₹236,915.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,756.00 | ₹285,313,124,000.00 | ₹3,160,074.00 |
Piramal Enterprises Limited | PEL | ₹1,213.80 | ₹275,141,756,400.00 | ₹2,508,951.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,610.00 | ₹251,254,990,000.00 | ₹444,446.00 |
Eris Lifesciences Limited | ERIS | ₹1,710.00 | ₹232,896,870,000.00 | ₹106,770.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,231.00 | ₹230,775,000,000.00 | ₹20,847.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹976.00 | ₹191,845,488,000.00 | ₹60,016.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,156.50 | ₹184,208,476,500.00 | ₹144,076.00 |
NATCO Pharma Limited | NATCOPHARM | ₹962.00 | ₹172,303,820,000.00 | ₹1,355,112.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹12,300.00 | ₹157,807,770,000.00 | ₹74,664.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,015.00 | ₹153,163,575,500.00 | ₹35,939.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹466.75 | ₹113,254,087,000.00 | ₹331,420.00 |
Procter & Gamble Health Limited | PGHL | ₹5,742.00 | ₹95,313,754,800.00 | ₹23,112.00 |
Shilpa Medicare Limited | SHILPAMED | ₹893.00 | ₹87,327,273,700.00 | ₹154,066.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹922.50 | ₹83,610,436,950.00 | ₹292,346.00 |
Strides Pharma Science Limited | STAR | ₹887.00 | ₹81,748,314,900.00 | ₹428,149.00 |
FDC Limited | FDC | ₹500.00 | ₹81,405,000,000.00 | ₹72,219.00 |
Suven Life Sciences Limited | SUVEN | ₹276.06 | ₹60,201,508,440.00 | ₹285,602.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹158.47 | ₹51,427,001,340.00 | ₹1,252,773.00 |
Innova Captab Limited | INNOVACAP | ₹874.65 | ₹50,051,785,025.00 | ₹46,543.00 |
Sequent Scientific Limited | SEQUENT | ₹183.97 | ₹46,048,610,850.00 | ₹343,786.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹474.80 | ₹43,334,996,000.00 | ₹158,293.00 |
Hikal Limited | HIKAL | ₹340.00 | ₹41,922,340,000.00 | ₹164,590.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,524.90 | ₹41,759,321,100.00 | ₹17,230.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹590.25 | ₹41,557,023,450.00 | ₹17,355.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹717.25 | ₹36,378,274,475.00 | ₹55,118.00 |
Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,272,200.00 | ₹50,065.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹62.60 | ₹34,301,920,400.00 | ₹1,983,956.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹664.45 | ₹31,995,260,850.00 | ₹589,713.00 |
Indoco Remedies Limited | INDOCO | ₹327.00 | ₹30,165,063,300.00 | ₹174,646.00 |
Alembic Limited | ALEMBICLTD | ₹117.00 | ₹30,043,493,883.00 | ₹332,513.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹90.96 | ₹26,699,215,920.00 | ₹1,227,006.00 |
Key Executives
Gender: male
Year Born: 1947
Gender: male
Year Born: 1962
Gender: male
Year Born: 1983
Gender: male
Year Born: 1963
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born: 1974
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Aarti Drugs Limited
The CEO is Prakash Moreshwar Patil.
The current price is ₹474.80.
The range is ₹312-635.
The market capitalization is ₹4,333.50 crores.
The dividend yield is 0.21%.
The P/E ratio is 25.80.
The company operates in the Healthcare sector.
Overview of Aarti Drugs Limited (ISIN: INE767A01016) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,333.50 crores and an average daily volume of 496,256 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.